A Fifty-Two-Week, Randomized, Placebo-Controlled Trial of Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis

Atul Deodhar, Lianne S Gensler, Jonathan Kay, Walter P Maksymowych, Nigil Haroon, Robert Landewé, Martin Rudwaleit, Stephen Hall, Lars Bauer, Bengt Hoepken, Natasha de Peyrecave, Brian Kilgallen, Désirée van der Heijde, Atul Deodhar, Lianne S Gensler, Jonathan Kay, Walter P Maksymowych, Nigil Haroon, Robert Landewé, Martin Rudwaleit, Stephen Hall, Lars Bauer, Bengt Hoepken, Natasha de Peyrecave, Brian Kilgallen, Désirée van der Heijde

Abstract

Objective: The natural history of nonradiographic axial spondyloarthritis (SpA) is incompletely characterized, and there are concerns that nonsteroidal antiinflammatory drugs provide inadequate disease control in patients with active disease. This study was undertaken to investigate the effects of certolizumab pegol (CZP), an anti-tumor necrosis factor treatment, in patients with nonradiographic axial SpA with objective signs of inflammation.

Methods: In this ongoing parallel-group double-blind study, adults with active disease were recruited from 80 centers in Australia, Europe, North America, and Taiwan, and were randomized 1:1 to receive placebo or CZP (400 mg at weeks 0, 2, and 4, followed by 200 mg every 2 weeks) in addition to nonbiologic background medication (NBBM). Switching to open-label CZP (or other biologic) or making background medication changes was permitted at any point during the trial, although changes before week 12 were discouraged. The primary end point was the proportion of patients achieving major improvement (MI) (i.e., a ≥2.0-point decrease in the score from baseline or achievement of the lowest possible score [0.6]) in the Ankylosing Spondylitis Disease Activity Score (ASDAS) at week 52.

Results: A total of 317 patients were randomized to receive placebo plus NBBM (n = 158) or CZP plus NBBM (n = 159). ASDAS-MI at week 52 was achieved in 47.2% (75 of 159) of CZP plus NBBM patients, which was significantly greater (P < 0.0001) than the 7.0% (11 of 158) of placebo plus NBBM patients in whom ASDAS-MI was achieved. Of the placebo plus NBBM patients, 60.8% (96 of 158) switched to open-label treatment before week 52 compared to 12.6% (20 of 159) of the CZP plus NBBM patients.

Conclusion: Adding CZP to background medication is superior to adding placebo in patients with active nonradiographic axial SpA. These results indicate that remission in nonradiographic axial SpA treated without biologics occurs infrequently, demonstrating the need for treatment beyond nonbiologic therapy.

Trial registration: ClinicalTrials.gov NCT02552212.

© 2019 The Authors. Arthritis & Rheumatology published by Wiley Periodicals, Inc. on behalf of American College of Rheumatology.

Figures

Figure 1
Figure 1
Disposition of the patients. † = some patients met/did not meet multiple eligibility criteria; therefore, patient numbers in the disposition of patients do not add up to the total number of ineligible patients. MRI = magnetic resonance imaging; CRP = C‐reactive protein; ASAS = Assessment of SpondyloArthritis international Society; axSpA = axial spondyloarthritis; BASDAI = Bath Ankylosing Spondylitis Disease Activity Index; PBO = placebo; NBBM = nonbiologic background medication; CZP = certolizumab pegol 200 mg.
Figure 2
Figure 2
Proportion of patients achieving A, major improvement in the Ankylosing Spondylitis Disease Activity Score (ASDAS‐MI) and B, 40% improvement in disease activity according to the Assessment of SpondyloArthritis international Society criteria (ASAS40) by week 52. P < 0.0001 for certolizumab pegol (CZP) versus placebo (PBO) at week 12 and week 52 for both ASDAS‐MI and ASAS40. NBBM = nonbiologic background medication.
Figure 3
Figure 3
Forest plot of major improvement in the Ankylosing Spondylitis Disease Activity Score (ASDAS‐MI) sensitivity analyses at week 52. 95% CI = 95% confidence interval; FAS = full analysis set; PBO = placebo; CZP = certolizumab pegol 200 mg; PPS = per protocol set; NBBM = nonbiologic background medication.

References

    1. Landewé R, Braun J, Deodhar A, Dougados M, Maksymowych WP, Mease PJ, et al. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24‐week results of a double‐blind randomised placebo‐controlled phase 3 study. Ann Rheum Dis 2014;73:39–47.
    1. Sieper J, Kivitz AJ, van Tubergen AM, Deodhar AA, Coteur G, Woltering F, et al. Rapid improvements in patient‐reported outcomes with certolizumab pegol in patients with axial spondyloarthritis, including ankylosing spondylitis and non‐radiographic axial spondyloarthritis: 24‐week results of a phase 3 double blind randomized placebo‐controlled study [abstract]. Value Health 2013;16 Suppl:A227.
    1. Baraliakos X, Braun J. Non‐radiographic axial spondyloarthritis and ankylosing spondylitis: what are the similarities and differences? RMD Open 2015;Suppl 1:e000053.
    1. Taurog JD, Chhabra A, Colbert RA. Ankylosing spondylitis and axial spondyloarthritis. N Engl J Med 2016;374:2563–74.
    1. Keat A, Bennett AN, Gaffney K, Marzo‐Ortega H, Sengupta R, Everiss T. Should axial spondyloarthritis without radiographic changes be treated with anti‐TNF agents? Rheumatol Int 2017;37:327–36.
    1. Wallman JK, Kapetanovic MC, Petersson IF, Geborek P, Kristensen LE. Comparison of non‐radiographic axial spondyloarthritis and ankylosing spondylitis patients: baseline characteristics, treatment adherence, and development of clinical variables during three years of anti‐TNF therapy in clinical practice. Arthritis Res Ther 2015;17:378.
    1. Ward MM, Deodhar A, Akl EA, Lui A, Ermann J, Gensler L, et al. American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheumatol 2016;68:282–98.
    1. Van der Heijde D, Ramiro S, Landewé R, Baraliakos X, van den Bosch F, Sepriano A, et al. 2016 update of the ASAS‐EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis 2017;76:978–91.
    1. Sepriano A, Regel A, van der Heijde D, Braun J, Baraliakos X, Landewé R, et al. Efficacy and safety of biological and targeted‐synthetic DMARDs: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis. RMD Open 2017;3:e000396.
    1. Sieper J, Braun J, Dougados M, Baeten D. Axial spondyloarthritis. Nat Rev Dis Primers 2015;1:15013.
    1. Rudwaleit M, Sieper J. Referral strategies for early diagnosis of axial spondyloarthritis. Nat Rev Rheumatol 2012;8:262–8.
    1. US Food and Drug Administration . FDA briefing document: Assessment of SpondyloArthritis international Society (ASAS) classification criteria for axial spondyloarthritis and the implications of using these criteria for drug approval. 2013. URL: .
    1. Kiltz U, Baraliakos X, Karakostas P, Igelmann M, Kalthoff L, Klink C, et al. Do patients with nonradiographic axial spondylarthritis differ from patients with ankylosing spondylitis? Arthritis Care Res (Hoboken) 2012;64:1415–22.
    1. Robinson PC, Bird P, Lim I, Saad N, Schachna L, Taylor AL, et al. Consensus statement on the investigation and management of non‐radiographic axial spondyloarthritis (nr‐axSpA). Int J Rheum Dis 2014;17:548–56.
    1. Sampaio‐Barros PD, Bortoluzzo AB, Conde RA, Costallat LT, Samara AM, Bertolo MB. Undifferentiated spondyloarthritis: a longterm followup. J Rheumatol 2010;37:1195–9.
    1. US Food and Drug Administration . Summary minutes of the Arthritis Advisory Committee meeting. 2013. URL: .
    1. Deodhar A, Reveille JD, van den Bosch F, Braun J, Burgos‐Vargas R, Caplan L, et al. The concept of axial spondyloarthritis: joint statement of the Spondyloarthritis Research and Treatment Network and the Assessment of SpondyloArthritis international Society in response to the US Food and Drug Administration's comments and concerns. Arthritis Rheumatol 2014;66:2649–56.
    1. Poddubnyy D, Gensler LS. Spontaneous, drug‐induced, and drug‐free remission in peripheral and axial spondyloarthritis. Best Pract Res Clin Rheumatol 2014;28:807–18.
    1. Rudwaleit M, van der Heijde D, Landewé R, Akkoc N, Brandt J, Chou CT, et al. The Assessment of SpondyloArthritis international Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 2011;70:25–31.
    1. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286–91.
    1. Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361–8.
    1. Lambert RG, Bakker PA, van der Heijde D, Weber U, Rudwaleit M, Hermann KG, et al. Defining active sacroiliitis on MRI for classification of axial spondyloarthritis: update by the ASAS MRI working group. Ann Rheum Dis 2016;75:1958–63.
    1. Lukas C, Landewé R, Sieper J, Dougados M, Davis J, Braun J, et al, for the Assessment of SpondyloArthritis international Society . Development of an ASAS‐endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis 2009;68:18–24.
    1. Machado P, Navarro‐Compán V, Landewé R, van Gaalen FA, Roux C, van der Heijde D. Calculating the Ankylosing Spondylitis Disease Activity Score if the conventional C‐reactive protein level is below the limit of detection or if high‐sensitivity C‐reactive protein is used: an analysis in the DESIR cohort. Arthritis Rheumatol 2015;67:408–13.
    1. Van der Heijde D, Lie E, Kvien TK, Sieper J, van den Bosch F, Listing J, et al. ASDAS, a highly discriminatory ASAS‐endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis 2009;68:1811–8.
    1. Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994;21:2281–5.
    1. Maksymowych WP, Inman RD, Salonen D, Dhillon S, Williams M, Stone M, et al. Spondyloarthritis Research Consortium of Canada magnetic resonance imaging index for assessment of sacroiliac joint inflammation in ankylosing spondylitis. Arthritis Rheum 2005;53:703–9.
    1. Doward LC, Spoorenberg A, Cook SA, Whalley D, Helliwell PS, Kay LJ, et al. Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis. Ann Rheum Dis 2003;62:20–6.
    1. Hurst NP, Kind P, Ruta D, Hunter M, Stubbings A. Measuring health‐related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ‐5D). Br J Rheumatol 1997;36:551–9.
    1. Ware JE Jr, Snow KK, Kosinski M, Gandek B. SF‐36 health survey: manual and interpretation guide. Boston: The Health Institute, New England Medical Center; 1993.
    1. Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A. Defining spinal mobility in ankylosing spondylitis (AS): the Bath AS Metrology Index. J Rheumatol 1994;21:1694–8.
    1. Heuft‐Dorenbosch L, Spoorenberg A, van Tubergen A, Landewe R, van ver Tempel H, Mielants H, et al. Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis 2003;62:127–32.
    1. Maxwell LJ, Zochling J, Boonen A, Singh JA, Veras MM, Tanjong Ghogomu E, et al. TNF‐α inhibitors for ankylosing spondylitis [review]. Cochrane Database Syst Rev 2015;CD005468.
    1. Van der Heijde D, Dougados M, Landewe R, Sieper J, Maksymowych WP, Rudwaleit M, et al. Sustained efficacy, safety and patient‐reported outcomes of certolizumab pegol in axial spondyloarthritis: 4‐year outcomes from RAPID‐axSpA. Rheumatology (Oxford) 2017;56:1498–509.
    1. Sieper J, van der Heijde D, Dougados M, Mease PJ, Maksymowych WP, Brown MA, et al. Efficacy and safety of adalimumab in patients with non‐radiographic axial spondyloarthritis: results of a randomised placebo‐controlled trial (ABILITY‐1). Ann Rheum Dis 2013;72:815–22.
    1. Sieper J, van der Heijde D, Dougados M, Maksymowych WP, Scott BB, Boice JA, et al. A randomized, double‐blind, placebo‐controlled, sixteen‐week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis. Arthritis Rheumatol 2015;67:2702–12.
    1. Dougados M, van der Heijde D, Sieper J, Braun J, Maksymowych WP, Citera G, et al. Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double‐blind, placebo‐controlled trial. Arthritis Rheumatol 2014;66:2091–102.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner